AdvisorShares Psychedelics ETF (PSIL)
- Previous Close
7.64 - Open
7.38 - Bid 7.00 x 800
- Ask 8.21 x 800
- Day's Range
7.27 - 7.27 - 52 Week Range
0.88 - 17.00 - Volume
2,824 - Avg. Volume
5,648 - Net Assets 5.04M
- NAV 7.34
- PE Ratio (TTM) --
- Yield 0.39%
- YTD Daily Total Return -44.30%
- Beta (5Y Monthly) 0.00
- Expense Ratio (net) 0.99%
The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and derivatives that have economic characteristics similar to such securities. The fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The fund is non-diversified.
AdvisorShares
Fund Family
Miscellaneous Sector
Fund Category
5.04M
Net Assets
2021-09-15
Inception Date
Performance Overview: PSIL
View MoreTrailing returns as of 9/30/2024. Category is Miscellaneous Sector.
People Also Watch
Holdings: PSIL
View MoreTop 10 Holdings (68.37% of Total Assets)
Sector Weightings
Recent News: PSIL
View More
Research Reports: PSIL
View MoreDaily – Vickers Top Insider Picks for 10/02/2024
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Raising target price to $136.00
INNOVATIVE INDUSTRIAL PROPER has an Investment Rating of BUY; a target price of $136.000000; an Industry Subrating of Low; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Low.
RatingPrice TargetJohnson & Johnson Earnings: Growth Outlook Slowing After Solid 2023, but Pipeline Holds Upside
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.
RatingPrice TargetJohnson & Johnson: Split Off of Consumer Unit Kenvue Likely Final Step in Unit’s Divestment
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.
RatingPrice Target